PHAXIAM Therapeutics Investor Relations Material
Latest events
Q2 2024
PHAXIAM Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from PHAXIAM Therapeutics SA
Access all reports
PHAXIAM Therapeutics S.A. is a biopharmaceutical company focused on developing innovative treatments for drug-resistant bacterial infections. Leveraging phages, which are viruses that specifically target and kill bacteria, the company is developing a portfolio aimed at combating some of the most challenging and resistant bacterial strains, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. PHAXIAM is also involved in advancing clinical-stage therapies, including eryaspase, which is being tested in late-stage clinical trials for conditions such as pancreatic cancer and acute lymphoblastic leukemia. The company is headquartered in Lyon, France, and its shares are listed on the Euronext Paris.
Latest articles
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
PHXM
Country
🇫🇷 France